Fund+ is an open-ended Fund for long term equity investment in innovative Life Sciences companies with a focus on Belgium. We want to create sustainable shareholders value, contribute to the development of a leadership position in the Life Sciences sector and generate a tangible, beneficial societal impact.
Location: Belgium, Flemish Brabant, Tienen
Employees: 1-10
Founded date: 2015
Investors 1
Mentions in press and media 8
Date | Title | Description | Source |
31.05.2022 | Minoryx Therapeutics closes €51M Series C round co-led by Co... | 31/05/2022 Press release YSIOS CAPITAL JOINS ITS PORTFOLIO COMPANY. MINORYX THERAPEUTICS, €51 MILL... | webcapital... |
03.05.2022 | Tubulis Closes €60 Million Series B Financing to Accelerate ... | May 3, 2022 MUNICH, GERMANY, May 3, 2022 – Tubulis today announced the successful completion of a €... | htgf.de/en... |
22.02.2022 | TargED Biopharmaceuticals raises EUR 39 Million in Series A ... | TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking throm... | hadeanvent... |
16.06.2020 | Alta Life Sciences invests in Ona Therapeutic’s €30M Series ... | Barcelona, Spain, June 16th 2020: Ona Therapeutics, which is focused on the discovery and developmen... | altals.com... |
26.09.2018 | Minoryx Therapeutics raises €21.3M in Series B funding round... | Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, to... | caixacapit... |
26.09.2018 | Minoryx cierra una ronda Serie B de €21,3M liderada por Fund... | 26/09/2018 Nota de prensa MINORYX CIERRA UNA RONDA SERIE B DE €21,3 MILLONES LIDERADA POR FUND+, A... | webcapital... |
05.09.2017 | Immunic Therapeutics gewinnt zwei weitere Investoren und kom... | Planegg-Martinsried, 5. September 2017: Immunic AG (Immunic Therapeutics), ein junges Biotechnologie... | bmp.com/de... |
- | Egle Therapeutics raises 40 million € Series A to develop Fi... | LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate Egle Therape... | bioqubeven... |